Several risk factors have been identified but the etiology and pathogenesis of Bacterial 15 vaginosis (BV) are still not completely understood, and the recurrence rate of BV remains 16 high despite adequate chemotherapy treatment. 17 The primary objective of the study was to assess the effectiveness of a new vaginal 18 medical device, which contains polycarbophil, 0.04 % lauryl glucoside, and glycerides 19 (Polybactum ® -Effik Italia), in reducing BV recurrence rate. 20 This was a multicenter, open label, not comparative study performed in Italy and Romania. 21 Female subjects over 18-years-old affected by recurrent BV were included. The latest 22 episode was diagnosed by Amsel criteria 6-9 days before the start of the study and treated 23 with vaginal metronidazole (gel 0.75% mg for 5 days or ovules 500 mg for 7 days). The 24 recurrence was defined by at least 2 episodes in the previous 12 months. Polybactum ® 25 vaginal ovules, day 1-4-7, were started within the 12th and the 24th hr after the end of 26 metronidazole therapy and repeated monthly for 3 cycles. 27 The first 41 patients enrolled were evaluated for an interim analysis 6 months after the 28 study started; 2 patients interrupted the trial, leaving 39 evaluable subjects. The 29 recurrence rate was significantly reduced compared to previous published data (10.26% vs 30 40% p<0.001). In 35 patients without recurrence, the assessment of Lactobacillus vaginal 31 flora performed by phase contrast microscopy evidenced a significant improvement form 32 baseline (p=0.022) The Investigator global assessment of tolerability was excellent in 38 33 out of 39 cases. 34 IMPORTANCE 35 Bacterial vaginosis (BV) is the most common vaginal disorder in women of childbearing 36 age. In BV, Lactobacillus species, which are predominant in a healthy vaginal flora, are 37 replaced by anaerobes, mainly Gardnerella vaginalis. BV is responsible for more than 60% 38 of vulvovaginal infections and has been linked to serious, potentially life-threatening 39 3 conditions, including: pelvic inflammatory disease, postoperative infections, acquisition and 40
INTRODUCTION
In any case, the Investigator could always decide to stop administering the medical device 144 for safety purposes or to prescribe other therapies if considered necessary for the patient's 145 health. 146 The Sponsor, Effik Italia, supplied the investigational product. Patients were reminded to 147 return all investigational product packages to the Investigator. At the end of the study, the 448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470 
